Company Overview and News

to your dashboard

Headline News

4 Best Marijuana Stocks to Play the Green Rush

2018-01-09 zacks
Whether its eating a gooey, chocolatey brownie or taking a few hits off a freshly rolled joint, it’s common knowledge that a lot of people like to get high. Many investors, however, have yet to “light up.” Some hesitate from adding marijuana stocks to their portfolio on apprehensions that pot companies are involved in scams or that it’s still deemed illegal by the federal government. (96-1)

S&P 500 index 2017 returns Vs Zacks, Barrons, Forbes, CNN Money, Fool

2018-01-08 valuewalk
Back in July, we published a review of various “top stocks” for 2017 and their performance halfway through the year. With 2017 now behind us, we decided to review the same picks for a final report card. The analysis includes the notable Barron’s Top 10, Zack’s Top 10, a Top 5 from CNN Money, a Top 5 from Motley Fool, a Top 10 from MSN experts, and a Top 7 from Forbes, which consisted of seven investment strategists making their top picks for the year. (426-0)

Horizons Marijuana Life Sciences Index ETF Is A Best Bet For The Passive Marijuana Investor

2018-01-03 seekingalpha
It is always difficult to “pull the trigger” and buy a stock or other financial instrument after a “gap up,” but put this ETF on your “watch list.”. (32-1)

Why Ganaxalone Is a Promising Drug Candidate

2017-12-27 marketrealist
Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017. This study in pediatric epilepsies showed a median decrease of 43% in seizure frequency in a 28-day period, which was the primary endpoint of the study. The secondary endpoint of the study, which was seizure-free days, showed an increase of 78%. (119-2)

What Analysts Recommend for Marinus Pharmaceuticals in December

2017-12-27 marketrealist
Marinus Pharmaceuticals (MRNS) is a clinical-stage biopharmaceutical company. The company’s clinical-stage product candidate, ganaxalone, is a modulator of the GABAA receptor. The GABAA receptor is a target in the brain associated with anti-seizure, anti-depression, and anti-anxiety effects. (119-0)

Jonathan Faison Positions For 2018: Faster FDA Approval, Emerging Sector In China Bode Well For Biotech Next Year

2017-12-20 seekingalpha
Despite recent doom and gloom talk that came as a result of the pullback in fall, it has still been a decent year. (482-1)

3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2018

2017-12-20 zacks
Although there are still a few days left for the year to end, 2017 has turned out to be pretty good for the pharma and biotech sector where FDA approvals are concerned. Till date, the regulatory agency has given its nod to 43 novel drugs, well above the 22 drugs approved last year. Immuno-oncology was a key focus area in 2017, whether it was to do with scientific conferences, clinical trial collaborations, acquisitions or FDA approvals. (132-3)

ROTY Edition 1 Volume 59: Updates And Trades

2017-12-07 seekingalpha
December had a decidedly rough start for the biotech sector and ROTY, which I discuss below. (102-3)

GW Pharma Results Set Up A Key 2019

2017-12-06 seekingalpha
Results show the company is sufficiently financed for the short term but additional finance required for medium term. (66-0)

Biotech Forum Daily Digest: Our Take On MiMedx

2017-12-05 seekingalpha
After a decent previous week, biotech slid on Monday as money rotated into energy and financial names. (106-3)

Your Daily Pharma Scoop: Loxo Data, GW Pharmaceuticals' Q4 Results, Zynerba Positive Data

2017-12-05 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one day earlier. (500-2)

The Bull Case Just Strengthened For This ROTY Contender

2017-12-04 seekingalpha
We delve into the implications of the new results presented at AES for ZYN002 in adult epilepsy patients with focal seizures. (30-0)

Therapix expects to have results of Tourette's drug trial by end of first quarter - Channel NewsAsia

2017-12-04 channelnewsasia
TEL AVIV: Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues. (30-1)

Zynerba Pharmaceuticals: 2 Pivotal Programs To Be Launched In 2018 Plus Upside In Epilepsy

2017-11-26 seekingalpha
Shares have risen by 50% in just a month since I suggested readers follow insiders back into the stock. (32-0)

Ovid Therapeutics: Is There More Upside After A 75% Gain In 3 Weeks?

2017-11-23 seekingalpha
Shares have risen by 75% since bringing this stock to the attention of readers three weeks ago. (388-4)

CUSIP: 98986X109